Evidence map›Paper›PMID 37950573›Full record

ArticleJournal of applied toxicology : JAT2024

Using particle dimensionality-based modeling to estimate lung carcinogenicity of 3D printer emissions.

Andrey A Korchevskiy, W Cary Hill, Matthew Hull, Arseniy Korchevskiy

Abstract read
In one paragraph

Article in Journal of applied toxicology : JAT, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrey A KorchevskiyChemistry & Industrial Hygiene, Inc., Arvada, Colorado, USA.ORCID 0000-0003-0456-3823
W Cary HillITA International, LLC, Blacksburg, Virginia, USA.
Matthew HullVirginia Tech, Institute for Critical Technology and Applied Science, Blacksburg, Virginia, USA.
Arseniy KorchevskiyColorado School of Mines, Golden, Colorado, USA.

Funding

NanoSafe Tested Third Party Verification Process for Characterizing Exposures to Products Containing Engineered NanomaterialsR44ES030650 · NIEHS · NANOSAFE, INC. · PI HILL, WILLIAM CARY · 2021 to 2022
$1.0M
National Institute of Environmental Health Sciences of the National Institutes of Health R44ES030650National Science Foundation (NSF) ECCS 1542100National Science Foundation (NSF) ECCS 2025151NIEHS NIH HHS R44 ES030650USACE Engineer Research and Development Center Environmental Laboratory W912HZ21C0061Virginia Tech National Center for Earth and Environmental Nanotechnology Infrastructure (NanoEarth)
6 · The paper itself

Abstract

The use of 3D printing technologies by industry and consumers is expanding. However, the approaches to assess the risk of lung carcinogenesis from the emissions of 3D printers have not yet been developed. The objective of the study was to demonstrate a methodology for modeling lung cancer risk related to specific exposure levels as derived from an experimental study of 3D printer emissions for various types of filaments (ABS, PLA, and PETG). The emissions of 15 filaments were assessed at varying extrusion temperatures for a total of 23 conditions in a Class 1,000 cleanroom following procedures described by ANSI/CAN/UL 2904. Three approaches were utilized for cancer risk estimation: (a) calculation based on PM2.5 and PM10 concentrations, (b) a proximity assessment based on the pulmonary deposition fraction, and (c) modeling based on the mass-weighted aerodynamic diameter of particles. The combined distribution of emitted particles had the mass median aerodynamic diameter (MMAD) of 0.35 μm, GSD 2.25. The average concentration of PM2.5 was 25.21 μg/m

Indexed as

Air Pollution, IndoorLung NeoplasmsNanotubes, CarbonThiogalactosidesHumansLungParticle SizeParticulate MatterPolyestersNanotubes, CarbonParticulate Matterphenylethylthio-beta-galactopyranosidePolyestersThiogalactosides3D printersadditive manufacturinglung cancerQSAR modelingultrafine particles

Identifiers

PMID37950573
PMCPMC11791719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.